| Catalog No. |
TD-HV986026 |
| Species reactivity |
Human |
| Applications |
Research Grade Biosimilar |
| Host species |
Humanized |
| Isotype |
IgG4-kappa |
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
PLAB, Placental bone morphogenetic protein, MIC1, NRG-1, PTGFB, NSAID-regulated gene 1 protein, GDF15, NAG-1, MIC-1, Prostate differentiation factor, NSAID-activated gene 1 protein, Growth/differentiation factor 15, Macrophage inhibitory cytokine 1, Placental TGF-beta, GDF-15, PDF |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
Q99988 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
CTL002,CTL-002,CTL002,CAS:2556646-63-8 |
| Background |
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |
抗体
试剂盒
多肽
蛋白
组织芯片
定制服务咨询